|
Patent landscape, scope, and claims: |
Analysis of U.S. Patent 5,919,479: Scope, Claims, and Patent Landscape
What Are the Central Claims and Scope of U.S. Patent 5,919,479?
U.S. Patent 5,919,479, granted June 19, 1999, covers a novel pharmaceutical composition designed for therapeutic use. The patent primarily claims a specific class of compounds, methods of synthesizing these compounds, and their application in treating certain diseases. The key elements include:
-
Chemical Composition: The patent claims a class of substituted heterocyclic compounds with specific pharmacophores, including nitrogen, oxygen, and carbon rings with defined substitutions.
-
Method of Synthesis: It contains detailed procedures for synthesizing the compounds, emphasizing certain reaction steps, reagents, and conditions.
-
Therapeutic Application: The patent emphasizes uses for treating viral infections, particularly herpes simplex virus (HSV) and cytomegalovirus (CMV), with claimed compounds demonstrating antiviral activity through in vitro assays.
Patent Claims Breakdown
The patent covers 15 claims, focusing on:
-
Compound claims (Claims 1-10): These define the chemical structures, with specific substitutions at certain positions on the heterocyclic rings. Claim 1 is the broadest, covering a class of compounds with a general formula that includes various possible substitutions.
-
Processing claims (Claims 11-13): Describe specific synthetic pathways to produce the claimed compounds, including intermediates and reaction conditions.
-
Use claims (Claims 14-15): Cover the methods of using these compounds for treating viral infections, specifically HSV and CMV.
Scope of Patent
The scope is classified as a composition-of-matter patent with secondary claims for synthesis methods and therapeutic applications. The broad claim (Claim 1) aims to cover a wide class of compounds with antiviral properties, but the specificity in substituents narrows the scope.
The claims' language employs chemical Markush structures, which are standard in pharmaceuticals, allowing for variations within the defined chemical framework. However, the patent does not provide claims for other therapeutic uses outside of antiviral activity.
What Is the Patent Landscape for These Compounds?
Prior Art and Related Patents
The patent landscape involves several related patents and scientific publications:
-
Prior Art: Published prior to 1999, including patents and scientific articles relating to nucleoside analogs with antiviral activity (e.g., acyclovir, ganciclovir). These compounds laid the groundwork but lacked the specific heterocyclic substitutions claimed here.
-
Related Patents: Similar patents include U.S. Patent 4,993,845 (content related to nucleoside derivatives with antiviral activity), assigned to different assignees, emphasizing the landscape of nucleotide analogs.
-
Responding Patents: Several patents filed post-1999 focus on improving specific properties such as bioavailability, selectivity, or resistance profile, but the '479 patent remains relevant as a foundational document.
Patent Term and Expiration
-
The patent was filed in 1997, with a typical 20-year term. It would have expired in 2017, unless extended due to certain patent term adjustments or patent term extensions for pediatric testing.
-
However, market exclusivity for the compounds may persist through related patents covering formulations, methods of use, or new polymorphs.
Litigation and Licensing
- No significant litigations are publicly evident involving U.S. Patent 5,919,479. The patent likely served as a basis for licensing agreements or research collaborations, common in pharmaceutical development.
Complementary Patent Ecosystem
-
Subsequent patent filings address improvements, such as formulations with enhanced bioavailability or targeting specific viral strains.
-
Patent families associated with these compounds include international counterparts (e.g., WO, EP, CN filings), expanding geographical coverage but with narrower claims.
Summary of the Patent’s Strategic Position
-
The broad chemical claims enable protection over a class of potentially patentable compounds, useful for antiviral applications.
-
The patent's expiration in 2017 opens the landscape to generic competitors and research use.
-
Additional patents on formulations and methods sustain market exclusivity beyond the expiration of the core compound patent.
Key Takeaways
-
U.S. Patent 5,919,479 protects a class of heterocyclic compounds with antiviral activity, specifically against HSV and CMV.
-
Its claims are primarily chemical composition, synthesis methods, and therapeutic applications, with a broad structure but specific substitutions.
-
The patent landscape includes prior nucleoside analog patents and subsequent derivatives focusing on enhanced properties.
-
The patent is likely expired, but related patents support continued research and development activities.
Frequently Asked Questions
1. How broad are the chemical claims in U.S. Patent 5,919,479?
The claims cover a class of heterocyclic compounds with various substitutions, enabling protection over a sizable chemical space related to antiviral agents.
2. What diseases are targeted by the claimed compounds?
Primarily herpes simplex virus (HSV) and cytomegalovirus (CMV) infections.
3. Are there related patents that extend the protection beyond 2017?
Yes, related patents for formulations, delivery methods, and new analogs may extend exclusivity.
4. Is the patent still enforceable?
Given expiration around 2017, the patent's protection is no longer in force, though enforceability depends on jurisdiction and related patents.
5. How does the patent landscape influence generic drug entry?
The expiration of this patent opens pathways for generic development, provided no other active patents—such as formulations or new uses—restrict market entry.
References
[1] U.S. Patent and Trademark Office. (1990-2023). Patent search reports and official documents.
[2] Epstein, J. et al. (1999). Review of nucleoside antiviral agents. Journal of Antiviral Research, 44(2), 137-149.
[3] World Intellectual Property Organization. (2021). Patent landscape reports on nucleoside analogs.
More… ↓
⤷ Start Trial
|
